Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elise Siegert

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
The Journal of Rheumatology|April 3, 2019
Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ ComplicationPia Moinzadeh, Kathrin Kuhr, Elise Siegert, et al.
Rheumatology (Oxford, England)|June 26, 2026
BCMA-directed therapy with cizutamig induces rapid improvement in long-standing systemic sclerosis-associated interstitial lung diseaseElpida Phithak, Fredrik Albach, Robert Biesen, et al.
Arthritis Research & Therapy|November 24, 2022
Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registryNorbert Blank, Marc Schmalzing, Pia Moinzadeh, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group StudyVeronika K Jaeger, Gabriele Valentini, Eric Hachulla, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
Rheumatology (Oxford, England)|February 10, 2025
Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritisFredrik N Albach, Ioanna Minopoulou, Artur Wilhelm, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Rheumatology (Oxford, England)|November 5, 2019
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group studyVeronika K Jaeger, Mohammed Tikly, Dong Xu, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR databaseQingran Yan, Cosimo Bruni, Alexandru Garaiman, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Rheumatology|April 3, 2019
Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ ComplicationPia Moinzadeh, Kathrin Kuhr, Elise Siegert, et al.
Rheumatology (Oxford, England)|June 26, 2026
BCMA-directed therapy with cizutamig induces rapid improvement in long-standing systemic sclerosis-associated interstitial lung diseaseElpida Phithak, Fredrik Albach, Robert Biesen, et al.
Arthritis Research & Therapy|November 24, 2022
Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registryNorbert Blank, Marc Schmalzing, Pia Moinzadeh, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group StudyVeronika K Jaeger, Gabriele Valentini, Eric Hachulla, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
Rheumatology (Oxford, England)|February 10, 2025
Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritisFredrik N Albach, Ioanna Minopoulou, Artur Wilhelm, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Rheumatology (Oxford, England)|November 5, 2019
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group studyVeronika K Jaeger, Mohammed Tikly, Dong Xu, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR databaseQingran Yan, Cosimo Bruni, Alexandru Garaiman, et al.
Pageof 8